As we approach the end of 2017, we look back with tremendous gratitude for the many friends and supporters of Novateur, especially for our valued clients, whom we consider our partners.
We had a great year and grew our practice in substantial ways in every possible metric. We worked with over 30 companies and investment groups conducting due diligence and providing product and project development advisory. We completed over 120 projects. Our clients raised over $100 M in capital, including one that successfully became public on a US stock exchange. Several companies also completed partnerships with larger pharma clients.
We believe Novateur is the solution for the “talent” challenge in Canada and other geographies where there is dearth of seasoned development and execution expertise and lack of a track record.
Novateur has a history of attracting world-class advisors. Only the very best join our team and work diligently to solve our client’s issues. Several of these world-class experts have become full time executives at Novateur and have relocated to Canada from the United States. We are pleased to contribute our part to reverse the Canadian “brain-drain”.
With over 120 active advisors and over 1,000 global advisors in our network, we can solve any life science problem effectively and efficiently.
Novateur is a very active and global group:
- Our advisors are part of many new start-ups and serve in active executive roles for our clients and partners.
- Our advisors attended over 200 conferences and seminars throughout the year and were speakers at several. I attended over 20 conferences and spoke at or chaired 6 conferences.
- Several of us participated in investments in our clients.
This year we saw many significant new drug approvals; FDA approved a gene therapy as well as a digital pill for the very first time. At the time of this article, with a month left to the end of the year, FDA had approved 40 new drugs in 2017 compared to 22 in 2016.
Our industry is breaking new ground every day. Together we are attacking mankind’s illnesses and developing new solutions for better health and longer, higher quality lives.
We are optimistic that 2018 will also be a great year and look forward to continued advisory opportunities to help many companies succeed.
Thank you all for your support. We look forward to seeing you at the JP Morgan conference and other venues throughout the next year.
Ali Ardakani is the Managing Director of Novateur Ventures and Director at the LifeSciences BC Board of Directors. His passions are his family, using technology to advance life science, travel, and helping entrepreneurs be successful.